Development of the Pancreas and Neonatal Diabetes

1st ESPE Advanced Seminar in Developmental Endocrinology, Paris, May 2007

Editor(s): Scharfmann R. (Paris) 
Shield J.P.H. (Bristol) 
Table of Contents
Vol. 12, No. , 2007
Section title: Paper
Shield JPH, Scharfmann R (eds): Development of the Pancreas and Neonatal Diabetes. Endocr Dev. Basel, Karger, 2007, vol 12, pp 12-23

Overview of Neonatal Diabetes

Hamilton-Shield J.
University of Bristol and Bristol Royal Hospital for Children, Bristol , UK

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Diabetes developing within the first 6 months of life is rarely, if ever, caused by a classic type 1 diabetesrelated autoimmune process. Currently, patients developing diabetes before 6 months of age are defined as having neonatal diabetes although this terminology possibly needs amending. Neonatal diabetes has a transient and permanent form and over 10 distinct genetic anomalies or mutations have been identified causing the disease. Transient neonatal diabetes can be caused by defects in the normal methylation pattern of an imprinted gene on chromosome 6 and by mutations in the 2 genes encoding the ß-cell ATP-sensitive potassium channel which is vital to normal glucose-stimulated insulin secretion. A genetic cause can be identified in over 90% of transient cases. Permanent neonatal diabetes can be caused by mutations in ß-cell transcription factors leading to abnormal pancreatic development often with other significant developmental anomalies, by defects in the glucose sensing, insulin secretory network and by accelerated ß-cell destruction. About 30% of cases of permanent diabetes have yet to have a genetic cause identified.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Pay-per-View Options
Direct payment This item at the regular price: USD 28.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 19.50